Side-by-side comparison of AI visibility scores, market position, and capabilities
Outpatient addiction and mental health treatment platform, Boston MA, raised $50M+. Value-based care model integrating SUD treatment with mental health support.
Eleanor Health is a Boston, Massachusetts-based behavioral health company founded in 2019 that provides value-based outpatient treatment for substance use disorder (SUD) combined with mental health care. The company has raised over $50 million and operates in multiple states through a hybrid model that combines telehealth with community-based care hubs staffed by multidisciplinary care teams. Eleanor Health treats addiction to opioids, alcohol, and other substances alongside co-occurring mental health conditions such as depression, anxiety, and PTSD.\n\nEleanor Health's care model is built around value-based contracts with Medicaid managed care organizations and commercial health plans, aligning the company's financial incentives with patient outcomes rather than visit volume. Care teams include addiction medicine specialists, therapists, care coordinators, and community health workers who support patients through recovery with a whole-person approach. The platform integrates medication-assisted treatment (MAT), individual and group therapy, and social needs navigation into a coordinated care program.\n\nThe company focuses on serving Medicaid populations with high rates of co-occurring substance use and mental health conditions, a population that historically experiences fragmented care across separate addiction and mental health service systems. Eleanor Health's integrated model is designed to reduce emergency department utilization, hospitalizations, and crisis episodes among high-need members. The company has partnered with several state Medicaid programs and commercial payers to expand access to its model across the Southeast and other regions.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies; processes millions of PA requests annually for specialty and retail prescriptions at no provider cost.
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.